Cash figures as of 2026-04-30. Database snapshot: 2026-09-22.
Price history
Loading HYFT daily closes…
Loading price history…
Pipeline assets
TATX-20
Discovery · ActiveModality: AI-designed antibody lead candidate
Partnerships Biotheus (Material Transfer and Evaluation Agreement)
Indications
hypoxic solid tumors(Discovery)
Status note Lead candidate being evaluated by Biotheus for development of novel bispecific antibodies; company out-licenses assets prior to clinical trials.
MDWK-03
Stage not disclosed · Active
Target SARS-CoV-2
Indications
SARS-CoV-2 infection(Stage not disclosed)
Status note Described as the most clinically advanced asset in the broader Vault by stage, in final drug product form; phase not stated.
Per-asset detail extracted from the 20-F filed 2026-07-23. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.